Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
World Journal of Gastroenterology · 2024
DOI: 10.3748/wjg.v30.i40.4367 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift World Journal of Gastroenterology, 2024. Verfasst von Ying Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Oxaliplatin, Oxonic Acid, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer have poor outcomes. Trastuzumab combined with chemotherapy is the first-line standard treatment for HER2-positive advanced gastric cancer. Inetetamab is a novel anti-HER2 drug, and its efficacy and safety in gastric cancer have not yet been reported. AIM To evaluate the efficacy and safety of the S-1 plus oxaliplatin (SOX) regimen combined with inetetamab as a first-line treatment for HER2-positive advanced gastric cancer. METHODS Thirty-eight patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma were randomly divided into two groups: One group received inetetamab combined with the SOX regimen, and the other group received trastuzumab combined with the SOX regimen. After 4-6 cycles, patients with stable disease received maintenance therapy. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints were the objective response rate, disease control rate, and adverse events (AEs). RESULTS Thirty-seven patients completed the trial, with 18 patients in the inetetamab group and 19 patients in the trastuzumab group. In the inetetamab group, the median PFS was 8.5 months, whereas it was 7.3 months in the trastuzumab group (P = 0.046); this difference was significant. The median OS in the inetetamab group vs the trastuzumab group was 15.4 months vs 14.3 months (P = 0. 33), and the objective response rate was 50% vs 42% (P = 0.63), respectively; these differences were not significant. Common AEs included leukopenia, thrombocytopenia, nausea, and vomiting. The incidence rates of grade ≥ 3 AEs were 56% in the inetetamab group and 47% in the trastuzumab group (P = 0.63), with no significant difference. CONCLUSION In the first-line treatment of HER2-positive advanced gastric cancer, inetetamab and trastuzumab showed comparable efficacy. The inetetamab group showed superior PFS, and both groups had good safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.
- Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China. liuhaiyan@sdfmu.edu.cn.
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.
Zitieren
APA
Kong, Y., Dong, Q., Jin, P., Li, M. Y., Ma, L., Yi, Q. J., Miao, Y. E., Liu, H. Y., & Liu, J. G. (2024). Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v30.i40.4367
Vancouver
Kong Y, Dong Q, Jin P, Li MY, Ma L, Yi QJ, et al. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World Journal of Gastroenterology. 2024. doi:10.3748/wjg.v30.i40.4367
BibTeX
@article{Kong2024,
author = {Kong, Ying and Dong, Qi and Jin, Peng and Li, Ming-Yan and Ma, Li and Yi, Qi-Jun and Miao, Yu-E and Liu, Hai-Yan and Liu, Jian-Gang},
title = {Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer},
journal = {World Journal of Gastroenterology},
year = {2024},
doi = {10.3748/wjg.v30.i40.4367}
}
EUVIMED